Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects

J Clin Oncol. 2007 Oct 10;25(29):4697-8; author reply 4698-9. doi: 10.1200/JCO.2007.12.8330.
No abstract available

Publication types

  • Case Reports
  • Comment
  • Letter

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / radiotherapy*
  • Adenocarcinoma / secondary
  • Adenocarcinoma / surgery
  • Back
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Carcinoma, Non-Small-Cell Lung / radiotherapy*
  • Chemotherapy, Adjuvant
  • Drug Eruptions / etiology
  • Drug Eruptions / prevention & control*
  • Epidermal Growth Factor / antagonists & inhibitors
  • Female
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / pathology
  • Lung Neoplasms / radiotherapy*
  • Lymphatic Metastasis
  • Middle Aged
  • Protein Kinase Inhibitors / adverse effects
  • Quinazolines / administration & dosage
  • Quinazolines / adverse effects*
  • Radiotherapy, Adjuvant
  • Skin / drug effects
  • Skin / radiation effects*

Substances

  • Protein Kinase Inhibitors
  • Quinazolines
  • Epidermal Growth Factor